Targeted Nucleic Acid Delivery Site-Specific Conjugation Technology Integrated Bioconjugation Platform
At BOC Sciences, we provide fully integrated Antibody-ASO Conjugate (AOC) development services, empowering pharmaceutical and biotech innovators to design and produce highly specific, next-generation nucleic acid therapeutics. By combining antibody-based targeted delivery with antisense oligonucleotide (ASO) gene modulation, our platform enables precise, tissue-selective delivery of RNA therapeutics that overcome traditional biodistribution barriers. Using advanced conjugation chemistries, proprietary linker systems, and state-of-the-art analytical platforms, we deliver end-to-end solutions-from antibody and ASO design, through conjugation process development, bioanalytical characterization, and GMP-ready manufacturing-helping clients efficiently transition from concept to clinic with maximum quality, speed, and regulatory compliance.
Traditional ASO and siRNA therapies face challenges such as poor tissue selectivity, rapid clearance, and limited cellular uptake. Antibody-ASO Conjugate technology addresses these issues by:
Enhancing Target Specificity: Directs nucleic acid payloads precisely to target cells or tissues via antibody-mediated recognition.
Improving Pharmacokinetics: Extends half-life and circulation stability through optimized linker and conjugation strategies.
Boosting Cellular Uptake: Promotes receptor-mediated endocytosis, enabling higher intracellular delivery of oligonucleotides.
Reducing Off-Target Effects: Minimizes systemic exposure and associated toxicity compared to unconjugated ASOs.
Streamlining Clinical Translation: Provides a modular platform compatible with diverse ASO chemistries and antibody formats.
By integrating immunoconjugation, oligonucleotide chemistry, and biophysical analytics, we deliver tailor-made AOC solutions that overcome key barriers in RNA therapeutics.
We provide a complete, modular suite of services to support every phase of your Antibody-ASO Conjugate (AOC) development—from discovery to GMP manufacturing.
Antibody & Target Selection
ASO Design & Optimization
Conjugation Strategy Development
Analytical Characterization & Quality Control
Process Development & Scale-Up
Bioanalytical & PK/PD EvaluationAt BOC Sciences, we follow a streamlined, scientifically proven process to ensure the efficient, high-quality development of Antibody-ASO Conjugates.
We begin by assessing your project goals, therapeutic indication, and target tissue to design a customized AOC development strategy. Our experts provide scientific and regulatory input to ensure alignment with both biological and commercial objectives.
Our team designs or sources high-affinity antibodies and optimizes ASO sequences for potency, stability, and minimal off-target risk. We employ computational prediction tools and modification strategies (e.g., LNA, 2'-O-methyl) to enhance delivery performance.
We establish the optimal site-specific conjugation or controlled stochastic approach using cleavable or non-cleavable linkers. This step defines the precise Oligo-to-Antibody Ratio (OAR) and ensures consistent conjugate quality across production batches.
Each conjugate is thoroughly characterized using LC-MS, CE, HIC, and hybridization assays to confirm structural integrity, purity, and bioactivity. We also validate receptor binding, internalization efficiency, and gene-silencing potency.
We develop scalable, reproducible conjugation and purification workflows. CMC documentation, stability studies, and technology transfer packages are prepared to support IND/CTA submissions.
GLP-compliant bioanalytical assays are provided for PK/PD, biodistribution, and toxicology studies. We support regulatory filings with complete analytical comparability data and preclinical reporting packages.
Our Antibody-ASO Conjugate platform enables precise, tissue-specific delivery of oligonucleotides through antibody-mediated recognition. This significantly enhances intracellular uptake while reducing systemic exposure, making RNA therapeutics safer and more effective for challenging indications such as neuromuscular and oncology disorders.
Using advanced site-specific conjugation chemistry, we achieve controlled attachment of ASOs to antibodies with defined stoichiometry and stability. This ensures uniform product quality, predictable pharmacokinetics, and smooth scalability from research to GMP manufacturing.
Our end-to-end bioconjugation workflow unifies antibody discovery, oligonucleotide synthesis, linker development, conjugation, purification, and analytics. By housing every step under one roof, we eliminate vendor fragmentation, shorten project timelines, and maintain full traceability throughout development.
By leveraging antibody targeting and optimized ASO chemistry, our conjugates deliver high-specificity gene silencing in desired cells while sparing healthy tissues. This translates into improved efficacy, lower dosing requirements, and superior safety margins compared to unconjugated ASO therapies.
An AOC is a hybrid molecule that links an antibody (for tissue-specific targeting) with an antisense oligonucleotide (ASO) (for gene expression regulation). This design enables highly selective delivery of RNA therapeutics to specific cells or tissues.
Both rely on antibody targeting, but ADC payloads are small-molecule cytotoxics, while AOC payloads are nucleic acids designed to modulate gene expression rather than kill cells. AOCs are therefore more suitable for chronic diseases requiring long-term correction of genetic dysfunction.
AOCs are currently in clinical development for neuromuscular, oncological, and CNS disorders, with expanding research into metabolic and autoimmune diseases. Their modular design allows rapid adaptation to new targets.
Key challenges include efficient intracellular delivery, endosomal escape, and maintaining conjugate stability without impairing antibody or ASO function. Our proprietary linker chemistry and analytical platforms are specifically designed to address these issues.
Yes. BOC Sciences offers complete AOC development solutions, covering antibody and ASO design, conjugation, analytical testing, process scale-up, and regulatory CMC support - from early discovery to GMP manufacturing readiness.
Partner with BOC Sciences to accelerate your Antibody-ASO Conjugate (AOC) innovation with our integrated bioconjugation platform, advanced conjugation chemistry, and expert analytical support. We help you transform scientific ideas into high-quality, reproducible AOC solutions that deliver precision, stability, and performance. Contact us today to learn how our customized AOC development services can power your next discovery in RNA-based drug design.
